Natalie M Brousseau1, Heather Farmer2, Allison Karpyn2, Jean-Philippe Laurenceau3, John F Kelly4, Elizabeth C Hill2, Valerie A Earnshaw2. 1. University of Delaware, 111 Alison Hall West, Newark, DE 19716, United States of America. Electronic address: nbrousseau@uconn.edu. 2. University of Delaware, 111 Alison Hall West, Newark, DE 19716, United States of America. 3. University of Delaware, 231 Wolf Hall, Newark, DE 19716, United States of America. 4. Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States of America; Massachussetts General Hospital, 60 Staniford Street, Boston, MA 02114, United States of America.
Abstract
INTRODUCTION: Methadone and buprenorphine/naloxone medications are among the most effective treatment options for opioid use disorders, yet many people remain misinformed about their benefits and hold negative perceptions about the use of medications to treat opioid use disorders. Such perceptions, especially negative perceptions based on misinformation, may be especially harmful or stigmatizing within the context of disclosure (i.e., telling another about one's opioid use disorder history or treatment), inhibiting important recovery outcomes and sources of social support. METHODS: Therefore, using the Disclosure Process Model as a framework, the current study seeks to characterize and compare participants' perceptions of stigmatizing reactions to their disclosures of MOUD use that stem from misinformation about methadone or buprenorphine/naloxone. Participants included people who are actively receiving MOUD as treatment. RESULTS: Results suggest that participants (N = 52) receiving both types of medications experienced similar stigmatizing reactions to disclosures. Participants also reported treatment consequences of misinformed reactions to their disclosure, such as dropping out of support groups (e.g., Narcotics Anonymous) or prematurely ending their medication use. Further, the paper provides participants' recommendations for avoiding or managing misinformed disclosure reactions. CONCLUSIONS: Short-term intervention efforts may promote strategies to manage misinformation, equipping individuals to respond to misinformation surrounding their medication use. Long-term interventions may target misinformation about methadone and buprenorphine/naloxone medications to increase health literacy, reduce stigma, and combat cultural ambivalence within communities, as well as promote recovery among people receiving medications for opioid use disorder.
INTRODUCTION: Methadone and buprenorphine/naloxone medications are among the most effective treatment options for opioid use disorders, yet many people remain misinformed about their benefits and hold negative perceptions about the use of medications to treat opioid use disorders. Such perceptions, especially negative perceptions based on misinformation, may be especially harmful or stigmatizing within the context of disclosure (i.e., telling another about one's opioid use disorder history or treatment), inhibiting important recovery outcomes and sources of social support. METHODS: Therefore, using the Disclosure Process Model as a framework, the current study seeks to characterize and compare participants' perceptions of stigmatizing reactions to their disclosures of MOUD use that stem from misinformation about methadone or buprenorphine/naloxone. Participants included people who are actively receiving MOUD as treatment. RESULTS: Results suggest that participants (N = 52) receiving both types of medications experienced similar stigmatizing reactions to disclosures. Participants also reported treatment consequences of misinformed reactions to their disclosure, such as dropping out of support groups (e.g., Narcotics Anonymous) or prematurely ending their medication use. Further, the paper provides participants' recommendations for avoiding or managing misinformed disclosure reactions. CONCLUSIONS: Short-term intervention efforts may promote strategies to manage misinformation, equipping individuals to respond to misinformation surrounding their medication use. Long-term interventions may target misinformation about methadone and buprenorphine/naloxone medications to increase health literacy, reduce stigma, and combat cultural ambivalence within communities, as well as promote recovery among people receiving medications for opioid use disorder.
Authors: Valerie A Earnshaw; Laura M Bogart; David Menino; John F Kelly; Stephenie R Chaudoir; Natalie Brousseau; Sharon Levy Journal: Int J Ment Health Addict Date: 2018-05-07 Impact factor: 3.836
Authors: Laura B Monico; Jan Gryczynski; Shannon Gwin Mitchell; Robert P Schwartz; Kevin E O'Grady; Jerome H Jaffe Journal: J Subst Abuse Treat Date: 2015-05-12
Authors: Carol T Miller; Sondra E Solomon; Susan E Varni; James J Hodge; F Andrew Knapp; Janice Y Bunn Journal: Soc Sci Med Date: 2016-06-16 Impact factor: 4.634
Authors: Karen R Sepucha; Dawn Stacey; Catharine F Clay; Yuchiao Chang; Carol Cosenza; Geoffrey Dervin; Janet Dorrwachter; Sandra Feibelmann; Jeffrey N Katz; Stephen A Kearing; Henrik Malchau; Monica Taljaard; Ivan Tomek; Peter Tugwell; Carrie A Levin Journal: BMC Musculoskelet Disord Date: 2011-07-05 Impact factor: 2.362